Open AccessSulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins
Author(s) -
Shamaa Marium M.
Publication year - 2021
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.13052
Subject(s) - imatinib , cancer research , tyrosine kinase , protein kinase b , medicine , sorafenib , pi3k/akt/mtor pathway , sulfasalazine , signal transduction , hepatocellular carcinoma , pharmacology , biology , receptor , microbiology and biotechnology , disease , myeloid leukemia , ulcerative colitis
The author investigated the potential anticarcinogenic effects of imatinib and sulfasalazine alone or in combination on HEPG2 and Huh‐7 cell lines. Combined use of both drugs inhibited cell growth and promoted apoptosis via the phosphoinositide 3‐kinase/protein kinase B, phosphorylated signal transducer and activator of translation 3 (p‐STAT‐3), breakpoint cluster region/Abelson proto‐oncogene and nuclear factor κB pathways. These results suggest that sulfasalazine synergistically potentiates the antitumor effect of imatinib.